Hepatitis B virus infection reactivation in patients under immunosuppressive therapies:Pathogenesis,screening,prevention and treatment

作     者：Anna Maria Spera 

作者机构：Infectious Disease UnitUniversitary Hospital OORR San Giovanni di Dio e Ruggi d'AragonaSalerno 84131Italy 

出 版 物：《World Journal of Virology》 (世界病毒学杂志)

年 卷 期：2022年第11卷第5期

页      面：275-282页

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：Hepatitis B Virus infection Reactivation Occult B infection Chronic B infection Immunosuppression Disease-modifying antirheumatic drugs 

摘      要：With a 5.3%of the global population involved,hepatitis B virus(HBV)is a major public health challenge requiring an urgent *** a possible acute phase,the natural history of HBV infection can progress in *** with overt or occult HBV infection can undergo HBV reactivation(HBVr)in course of immunosuppressive treatments that,apart from oncological and hematological diseases,are also used in rheumatologic,gastrointestinal,neurological and dermatological settings,as well as to treat severe acute respiratory syndrome coronavirus 2 *** risk of HBV reactivation is related to the immune status of the patient and the baseline HBV infection *** aim of the present paper is to investigate the risk of HBVr in those not oncological settings in order to suggest strategies for preventing and treating this *** main studies about HBVr for patients with occult hepatitis B infection and chronic HBV infection affected by non-oncologic diseases eligible for immunosuppressive treatment have been *** occurrence of this challenging event can be reduced screening the population eligible for immunosuppressant to assess the best strategies according to any virological *** prospective studies are needed to increase data on the risk of HBVr related to newer immunomodulant agents employed in non-oncological setting.